Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Ulrika Stierner

Physician

Ulrika Stierner
Physician
+46 31-342 1000

Postal Address: Su sahlgrenska, 41345 Göteborg
Visiting Address: Jubileumsklin, Blå str 2a SU , Göteborg


Department of Oncology at Institute of Clinical Sciences (More Information)
Sahlgrenska Universitetssjukhuset
413 45 Göteborg
0313428503
Visiting Address: Blå stråket 2 SU/Jubileusklin , 413 45 Göteborg

Latest publications

Real-world data on PD-1 inhibitor therapy in metastatic melanoma
A. Arheden, J. Skalenius, Sara Bjursten, Ulrika Stierner, Lars Ny et al.
Acta Oncologica, Journal article 2019
Journal article

Accelerated or conventional whole brain irradiation of malignant melanoma.
Ragnar Hultborn, Johanna Sand, Sara Kinhult, Lotta Lundgren, Ulrika Stierner et al.
Acta oncologica (Stockholm, Sweden), Journal article 2017
Journal article

Melanomincidensen fortsätter att stiga.
Hildur Helgadottir, Ulrika Stierner
Lakartidningen, Magazine article 2017
Magazine article

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
Y. H. Xue, L. Martelotto, T. Baslan, A. Vides, M. Solomon et al.
Nat Med, Journal article 2017
Journal article

Glycosaminoglycan Profiling in Patients' Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma
Francesco Gatto, N. Volpi, H. Nilsson, Intawat Nookaew, M. Maruzzo et al.
Cell Reports, Journal article 2016
Journal article

Showing 21 - 30 of 60

2013

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
Yvonne Brandberg, Hemming Johansson, Steinar Aamdal, Lars Bastholt, Michaela Hernberg et al.
Acta oncologica (Stockholm, Sweden), Journal article 2013
Journal article

2012

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Viktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, Kurt Miller, Jean-Pascal Machiels et al.
European journal of cancer (Oxford, England : 1990), Journal article 2012
Journal article

Improved survival with MEK inhibition in BRAF-mutated melanoma.
Keith T Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe et al.
The New England journal of medicine, Journal article 2012
Journal article

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Hege S Haugnes, Anna Laurell, Ulrika Stierner, Roy M Bremnes, Olav Dahl et al.
Acta oncologica (Stockholm, Sweden), Journal article 2012
Journal article

2011

Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group (SWENOTECA).
Torgrim Tandstad, Rune Smaaland, Arne Solberg, Roy M Bremnes, Carl W Langberg et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Journal article 2011
Journal article

Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.
Sven-Erik Olofsson, Torgrim Tandstad, Mats Jerkeman, Olav Dahl, Olof Ståhl et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Magazine article 2011
Magazine article

Showing 21 - 30 of 60

Page Manager: Katarina Olinder Eriksson|Last update: 3/28/2013
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?